Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma
To describe the tumor tissue saturation by MEDI-522 in patients with advanced malignant melanoma.
Malignant Melanoma
BIOLOGICAL: MEDI-522
The primary outcome of this study is to describe the tumor tissue saturation by MEDI-522 in patients with advanced malignant melanoma., Baseline to disease progression
Describe tumor and endothelial cell viability induced by MEDI-522., Baseline and two post-therapy points after week 3 and at time of 1st disease progression
To describe the tumor tissue saturation by MEDI-522 in patients with advanced malignant melanoma.